Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9934
Title: Liver metabolic activity changes over time with neoadjuvant therapy in locally advanced rectal cancer
Authors: Demir, Y.
Sürücü, E.
Şengöz, Tarık
Koç, M.
Kaya, G.C.
Keywords: 18F-FDG PET/CT
Dual time
Lean body mass corrected standardized uptake value
Locally advanced rectal cancer
Standardized uptake value
fluorodeoxyglucose f 18
adjuvant chemoradiotherapy
adult
aged
cancer staging
computer assisted tomography
drug effects
female
human
liver
male
metabolism
middle aged
multimodal imaging
neoadjuvant therapy
pathology
positron emission tomography
radiation response
Rectal Neoplasms
retrospective study
scintiscanning
time factor
very elderly
Adult
Aged
Aged, 80 and over
Chemoradiotherapy, Adjuvant
Female
Fluorodeoxyglucose F18
Humans
Liver
Male
Middle Aged
Multimodal Imaging
Neoadjuvant Therapy
Neoplasm Staging
Positron-Emission Tomography
Retrospective Studies
Time Factors
Tomography, X-Ray Computed
Publisher: Lippincott Williams and Wilkins
Abstract: Objective The aim of this study was to evaluate, using PET/computed tomography (CT), changes in liver metabolic activity in patients with locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (CRT). Patients and methods A total of 29 biopsy-proven LARC patients between 2009 and 2012 were studied. Liver standardized uptake values (SUVs) and SUVs adjusted for lean body mass (SULs) were obtained from PET/CT images obtained at 1 h (early) and 2 h (late) after 18F-fluorodeoxyglucose (18F-FDG) administration both before and after neoadjuvant CRT. Age, sex, BMI, lean body mass, blood glucose level, and 18F-FDG dose, which can influence liver SUVs and SULs, were also analyzed. Results Fourteen (48%) men and 15 (52%) women with a mean age of 62±11 years (range 34-80 years) were included in the study. The mean SUVs and SULs were significantly decreased in the late scans. Sex was significantly correlated with the mean liver SUV in early and late scans. The mean SUV differed significantly between male and female patients in early and late images (P<0.05). In a multivariate stepwise regression analysis, only liver SUVs (maximum and mean) were significantly associated with BMI before and after therapy. SUVs were significantly higher in the high (?25) BMI group after but not before therapy. Mean SUL was not influenced by BMI. Conclusion Liver 18F-FDG uptake is consistent before and after neoadjuvant CRT therapy in patients with LARC. When assessing response to therapy and using liver metabolic activity to indicate background activity, BMI should be considered as it can influence liver metabolic activity. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
URI: https://hdl.handle.net/11499/9934
https://doi.org/10.1097/MNM.0000000000000412
ISSN: 0143-3636
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

2
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

2
checked on Nov 16, 2024

Page view(s)

58
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.